Compare MTNB & VTAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTNB | VTAK |
|---|---|---|
| Founded | 2013 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 3.0M |
| IPO Year | 2014 | 2018 |
| Metric | MTNB | VTAK |
|---|---|---|
| Price | $0.62 | $0.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 294.9K | 58.3K |
| Earning Date | 05-14-2026 | 08-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 59.84 | ★ 89.53 |
| EPS | ★ N/A | N/A |
| Revenue | $119,750.00 | ★ $442,000.00 |
| Revenue This Year | N/A | $1,170.33 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 3057.14 |
| 52 Week Low | $0.48 | $0.15 |
| 52 Week High | $3.09 | $4.31 |
| Indicator | MTNB | VTAK |
|---|---|---|
| Relative Strength Index (RSI) | 58.10 | 38.36 |
| Support Level | $0.55 | $0.79 |
| Resistance Level | $0.66 | $1.28 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 57.87 | 18.59 |
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
Catheter Precision Inc is engaged in the design, manufacture, and sale of medical technologies focused in the field of cardiac electrophysiology, or EP. The company's two primary products include the VIVO System and LockeT. The VIVO System, which is an acronym for View into Ventricular Onset System(VIVO or VIVO System), is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its newest product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure.